1_img1424895986.jpg 2_img1424896008.jpg 3_img1424896028.jpg 4_img1424896053.jpg
ГЛЕДФАРМ ЛТД intro pharmacovigilance logo-img
  • 1-img1423128723_img1424877095.jpg
  • 2-img1423128732_img1424877082.jpg
  • 3-img1423128813_img1424877070.jpg
  • 4-img1423128825_img1424877057.jpg
  • analiz111_img1422534233.jpg

LEFNO tablets


  • Active phase of rheumatoid arthritis in adults, active phase of psoriatic arthritis.
  • Recent or concomitant treatment with hepatotoxic or hematotoxic disease-modifying antirheumatic drugs (DMARDs) (e.g. methotrexate) may increase the risk of serious adverse reactions, therefore, the beginning of treatment with leflunomide should be carefully considered, taking into account the aspects of benefit/risk.
  • Besides, the transfer from leflunomide to another DMARD without the elimination procedure (see section “Peculiarities of use”) may also increase the risk of serious adverse effects, even after a long period since the transfer.

1 tablet contains leflunomide 20 mg. Immunosuppressive agents

View instructions Dounload instruction
All Preparations